Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

Table 2 Virological, biochemical responses and severity scores

Characteristics	Entecavir (n = 65)	Lamivudine (n = 54)	t/χ2/z	P value
Virological
Serum HBV DNA level (log10 copies/mL)
Day 15	4.6 ± 1.1	5.4 ± 1.2	3.790	< 0.001
Day 30	3.9 ± 1.0	4.8 ± 1.3	4.266	< 0.001
Day 45	3.6 ± 0.8	4.5 ± 1.0	5.454	< 0.001
Day 60	3.4 ± 0.5	4.4 ± 0.9	7.653	< 0.001
Undetectable HBV DNA n (%)
Day 15	3 (4.6)	0 (0.0)	1.024	0.312
Day 30	15 (23.1)	6 (11.1)	2.906	0.088
Day 45	21 (32.3)	8 (14.8)	4.897	0.027
Day 60	24 (36.9)	9 (16.7)	6.039	0.014
Biochemical
Serum ALT level (U/L)
Day 15	187.4 ± 67.5	231.6 ± 81.1	3.231	0.002
Day 30	86.2 ± 22.4	94.7 ± 37.3	1.410	0.163
Day 45	54.4 ± 19.6	60.8 ± 28.7	1.222	0.226
Day 60	45.1 ± 20.8	51.6 ± 22.3	1.455	0.149
Severity
CTP score
Day 15	10.4 ± 2.7	10.2 ± 3.4	0.348	0.348
Day 30	8.7 ± 3.6	9.9 ± 4.2	1.678	0.096
Day 45	7.4 ± 2.1	8.5 ± 3.7	2.035	0.044
Day 60	6.6 ± 2.4	8.2 ± 3.5	2.478	0.016
MELD score
Day 15	25.2 ± 7.1	25.7 ± 8.4	0.350	0.727
Day 30	22.6 ± 6.7	24.5 ± 7.2	1.489	0.139
Day 45	17.8 ± 7.4	20.6 ± 8.2	1.956	0.052
Day 60	13.7 ± 4.6	16.1 ± 6.5	2.352	0.020

All values are expressed as mean ± SD. ALT: Alanine aminotransferase; CTP: Child-Turcotte Pugh; MELD: Model for end-stage liver disease.